journal
MENU ▼
Read by QxMD icon Read
search

International Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28929314/radiation-therapy-versus-surgery-for-patients-with-cervical-squamous-cell-carcinoma-who-have-undergone-neoadjuvant-chemotherapy-revisited
#1
Yu Furuta, Yukiharu Todo, Hiroyuki Yamazaki, Chisa Shimada, Sho Takeshita, Kazuhira Okamoto, Hidenori Kato
BACKGROUND: The therapeutic significance of neoadjuvant chemotherapy (NAC) followed by radiation therapy (RT) was negated during the early 1990s. Here, we compared post-NAC RT to surgery for chemo-sensitive cervical squamous cell carcinoma (SCC). METHODS: This study included 79 consecutive patients with cervical SCC who were treated by NAC followed by surgery (n = 49) or by definitive RT (n = 30). We compared characteristics and survival outcomes between the surgery and RT groups by their responses to NAC...
September 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28913565/a-retrospective-analysis-of-ramucirumab-monotherapy-in-previously-treated-japanese-patients-with-advanced-or-metastatic-gastric-adenocarcinoma
#2
Satoshi Murahashi, Daisuke Takahari, Takeru Wakatsuki, Naoki Fukuda, Takashi Ichimura, Mariko Ogura, Masato Ozaka, Eiji Shinozaki, Izuma Nakayama, Tomohiro Matsushima, Hiroki Osumi, Keisho Chin, Kensei Yamaguchi
BACKGROUND: The REGARD trial demonstrated that ramucirumab monotherapy improved both overall survival (OS) and progression-free survival (PFS) compared with best supportive care plus placebo as second-line treatment for patients with advanced gastric cancer. However, the efficacy and safety of ramucirumab monotherapy for previously treated Japanese patients with advanced gastric cancer remains unknown. METHODS: Previously treated Japanese patients with advanced gastric cancer who received ramucirumab monotherapy between June 2015 and March 2016 at the Cancer Institute Hospital were enrolled in the study...
September 14, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28884397/brca1-gene-function-and-deficiency
#3
REVIEW
Miho Takaoka, Yoshio Miki
The BRCA1 protein, a hereditary breast and ovarian cancer-causing gene product, is known as a multifunctional protein that performs various functions in cells. It is well known, along with BRCA 2, to cause hereditary breast and ovarian cancer, but here we will specifically focus on BRCA1. We introduce the mechanism and the latest report on homologous recombination repair, replication, involvement in checkpoint regulation, transcription, chromatin remodeling, and cytoplasmic function (centrosome regulation, apoptosis, selective autophagy), and consider the possibility of carcinogenesis from inhibition of the intracellular functions in each...
September 7, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28875240/potential-predictive-factors-for-microvascular-invasion-in-hepatocellular-carcinoma-classified-within-the-milan-criteria
#4
Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shinichiro Yamada, Yu Saito, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Mitsuo Shimada
BACKGROUND: Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. METHODS: One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study...
September 5, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28871342/a-systematic-review-of-publications-on-charged-particle-therapy-for-hepatocellular-carcinoma
#5
REVIEW
Hiroshi Igaki, Masashi Mizumoto, Toshiyuki Okumura, Kiyoshi Hasegawa, Norihiro Kokudo, Hideyuki Sakurai
Charged particle therapy (proton beam therapy and carbon ion therapy) is a form of radiotherapy which has the unique characteristic of superior depth dose distribution, and has been used for the treatment of hepatocellular carcinoma (HCC) in a limited number of patients, especially in Japan. We undertook a systematic review to define the clinical utility of charged particle therapy for patients with HCC. We searched the MEDLINE database from 1983 to June 2016 to identify clinical studies on charged particle therapy for HCC...
September 4, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28864833/impact-of-multiple-malignancies-on-surgical-outcomes-in-patients-with-1%C3%A2-cm-or-smaller-non-small-cell-lung-cancer
#6
Takuma Tsukioka, Nobuhiro Izumi, Shinjiro Mizuguchi, Chung Kyukwang, Hiroaki Komatsu, Michihito Toda, Kantaro Hara, Hikaru Miyamoto, Noritoshi Nishiyama
BACKGROUND: Because most patients with small-sized non-small cell lung cancer (NSCLC) are asymptomatic, their lesions are detected by cancer screenings or routine checkups for other diseases. Incidences of multiple malignancies have been reported to be 27% in patients with stage I-III NSCLC. Some patients have treatment histories for other malignancies, and their small-sized NSCLC was incidentally detected during follow-up. There is no established report regarding the influence of multiple malignancies on small-sized NSCLC prognosis...
September 1, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28856495/significance-of-multiple-preoperative-laboratory-abnormalities-as-prognostic-indicators-in-patients-with-urothelial-carcinoma-of-the-upper-urinary-tract-following-radical-nephroureterectomy
#7
Masatomo Nishikawa, Hideaki Miyake, Toshifumi Kurahashi, Masato Fujisawa
BACKGROUND: The aim of this study was to investigate the prognostic significance of multiple preoperative laboratory abnormalities in upper urinary tract urothelial carcinoma (UUTUC) patients. METHODS: This study included a total of 135 consecutive patients with clinically localized UUTUC who underwent radical nephroureterectomy (RNU). The impact of several preoperative blood-based markers in addition to conventional clinical factors on extravesical recurrence-free survival (eRFS) in these patients was retrospectively evaluated...
August 30, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28849281/the-insufficient-prognostic-power-of-stenosis-in-patients-with-esophageal-cancer
#8
LETTER
Jun-Feng Wang, Qiang-Bo Kan
No abstract text is available yet for this article.
August 28, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28840357/hereditary-breast-cancer-molecular-biology-and-management-update
#9
REVIEW
Hiroko Yamashita
No abstract text is available yet for this article.
August 24, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28836024/prognostic-factors-for-disease-free-and-overall-survival-of-patients-with-uterine-carcinosarcoma
#10
Yavuz Emre Şükür, Salih Taşkın, Bulut Varlı, Can Ateş, Mete Güngör, Fırat Ortaç
BACKGROUND: Uterine carcinosarcoma (UCS) is a relatively rare and very aggressive tumor. The predictors of survival for patients with UCS have not been determined clearly yet. The aim of the present study was to investigate the possible predictors of disease-free survival (DFS) and overall survival (OS) for patients with UCS. METHODS AND MATERIALS: All patients with UCS who were treated surgically at a university-based Gynecology Oncology Clinic between January 2008 and December 2014 were recruited into this retrospective cohort study...
August 23, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28823027/a-prospective-study-of-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-malignant-lymphoma-patients-following-highly-emetogenic-chemotherapy
#11
Tsutomu Takahashi, Takahiro Okada, Fumiyoshi Ikejiri, Shunsuke Ito, Yusuke Okada, Fumimasa Takahashi, Satoshi Kumanomido, Yumi Jo, Koji Adachi, Chie Onishi, Koshi Kawakami, Takaaki Miyake, Masaya Inoue, Ritsuro Suzuki, Junji Suzumiya
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancer patients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancer patients treated with cyclophosphamide and anthracycline, but there is little data for malignant lymphoma. We conducted a prospective phase 2 study at a single institution to clarify the efficacy and safety of palonosetron in lymphoma patients...
August 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28799063/clinical-outcomes-of-patients-with-epithelioid-sarcomas-impact-and-management-of-nodal-metastasis
#12
Hidetatsu Outani, Yoshinori Imura, Takaaki Tanaka, Satoshi Takenaka, Kazuya Oshima, Kenichiro Hamada, Shigeki Kakunaga, Susumu Joyama, Norifumi Naka, Ikuo Kudawara, Takafumi Ueda, Nobuhito Araki, Hideki Yoshikawa
PURPOSE: An epithelioid sarcoma is a rare histological subtype of a soft tissue sarcoma with a high local recurrence rate, which frequently shows lymph node metastasis. However, because of the rarity of this tumor, the impact of nodal metastasis and its appropriate management remain unclear. The present study investigated the clinical outcomes of patients with epithelioid sarcomas, with a focus on lymph node metastasis. METHODS: We retrospectively evaluated the clinical outcomes of 27 patients with epithelioid sarcomas treated between 1985 and 2015...
August 10, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28795280/the-use-of-neoadjuvant-therapy-for-resectable-locally-advanced-thoracic-esophageal-squamous-cell-carcinoma-in-an-analysis-of-5016-patients-from-305-designated-cancer-care-hospitals-in-japan
#13
Yoichiro Tsukada, Takahiro Higashi, Hideaki Shimada, Yoshinori Kikuchi, Atsuro Terahara
BACKGROUND: Recent studies have shown the benefits of neoadjuvant therapy with chemotherapy or chemoradiotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC). The aim of our study was to elucidate the use of neoadjuvant therapy for thoracic ESCC in Japan. METHODS: Data on patients with stage IB-III thoracic ESCC were retrieved from the national database of hospital-based cancer registries combined with claims data between 2012 and 2013...
August 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28791509/feasibility-of-dose-dense-epirubicin-and-cyclophosphamide-with-subcutaneous-pegfilgrastim-3-6%C3%A2-mg-support-a-single-center-prospective-study-in-japan
#14
Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takefumi Mizutani, Tomoya Shimokata, Hironori Hayashi, Osamu Maeda, Yuichi Ando
BACKGROUND: Dose-dense chemotherapy consisting of a combination of epirubicin and cyclophosphamide (EC) improves the survival of patients with breast cancer. Although pegfilgrastim was used at a subcutaneous dose of 6.0 mg in a pivotal study of dose-dense EC treatment, pegfilgrastim at a dose of 3.6 mg has been approved in Japan. We have assessed the feasibility of dose-dense EC treatment supported with a 3.6 mg dose of pegfilgrastim by evaluating the relative dose intensity (RDI) and safety of the treatment, together with measuring the pegfilgrastim concentrations remaining on the day of starting the next cycle of chemotherapy...
August 8, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28791497/low-preoperative-serum-cholesterol-level-is-associated-with-aggressive-pathologic-features-and-poor-cancer-specific-survival-in-patients-with-surgically-treated-renal-cell-carcinoma
#15
Ho Won Kang, Sung Pil Seo, Won Tae Kim, Seok Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Eu Chang Hwang, Seok Ho Kang, Sung-Hoo Hong, Jinsoo Chung, Tae Gyun Kwon, Hyeon Hoe Kim, Cheol Kwak, Seok-Soo Byun, Yong-June Kim
BACKGROUND: The prognostic implications of preoperative serum total cholesterol (TC) level in patients with renal cell carcinoma (RCC) remain poorly understood. We investigated the prognostic role of preoperative serum TC in patients with surgically treated RCC from a large, multi-institutional Korean collaboration. PATIENTS AND METHODS: A database of 3064 patients with RCC who underwent radical or partial nephrectomy between 1999 and 2011 at eight academic centers was analyzed...
August 8, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28770408/phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer
#16
Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles...
August 2, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28758177/the-5-year-outcomes-of-moderately-hypofractionated-radiotherapy-66%C3%A2-gy-in-22-fractions-3-fractions-per-week-for-localized-prostate-cancer-a-retrospective-study
#17
Yaichiro Hashimoto, Atsushi Motegi, Tetsuo Akimoto, Norio Mitsuhashi, Junpei Iizuka, Kazunari Tanabe, Yuka Ishii, Sawa Kono, Sachiko Izumi, Kumiko Karasawa
BACKGROUND: Hypofractionated radiotherapy using fewer and larger fractional doses may be more beneficial than conventional external-beam radiotherapy for localized prostate cancer. We evaluated the 5-year outcomes of moderately hypofractionated radiotherapy for localized prostate cancer. METHODS: We retrospectively evaluated 195 patients with localized prostate cancer (T1-3N0M0) who underwent intensity-modulated radiotherapy (IMRT) (66 Gy delivered in fractions of 3 Gy every other weekday) between May 2005 and December 2011...
July 31, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28756594/decreased-acute-toxicities-of-intensity-modulated-radiation-therapy-for-localized-prostate-cancer-with-prostate-based-versus-bone-based-image-guidance
#18
Kiyonao Nakamura, Takashi Mizowaki, Haruo Inokuchi, Itaru Ikeda, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa, Masahiro Hiraoka
BACKGROUND: Intensity-modulated radiation therapy (IMRT) is a major therapeutic option for localized prostate cancer. Image-guided radiation therapy (IGRT) allows tumor visualization and corrects the errors caused by daily internal movement of the prostate. The current study retrospectively compared the acute toxicities and biochemical tumor control outcomes of prostate IMRT achieved using two IGRT techniques: bony structure-based IGRT (B-IGRT) and prostate-based IGRT (P-IGRT). METHODS: Between February 2011 and July 2014, 96 patients with low- or intermediate-risk prostate cancer were treated using P-IGRT based on cone-beam computed tomography (CBCT; 76 Gy) without fiducial markers...
July 29, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28755069/erratum-to-sarcopenia-but-not-visceral-fat-amount-is-a-risk-factor-of-postoperative-complications-after-major-hepatectomy
#19
Takaaki Higashi, Hiromitsu Hayashi, Katsunobu Taki, Keita Sakamoto, Hideyuki Kuroki, Hidetoshi Nitta, Daisuke Hashimoto, Akira Chikamoto, Toru Beppu, Hideo Baba
No abstract text is available yet for this article.
July 28, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28752352/presurgical-axitinib-therapy-increases-fibrotic-reactions-within-tumor-thrombus-in-renal-cell-carcinoma-with-thrombus-extending-to-the-inferior-vena-cava
#20
Yoshimi Tanaka, Shingo Hatakeyama, Shogo Hosogoe, Toshikazu Tanaka, Itsuto Hamano, Ayumu Kusaka, Hiromich Iwamura, Naoki Fujita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama
BACKGROUND: Clinical benefits of presurgical axitinib therapy for renal cell carcinoma (RCC) extending into the inferior vena cava (IVC) remain unclear. We aimed to investigate surgical benefits and pathological antitumor effects of presurgical axitinib therapy for RCC with IVC thrombus. METHODS: Of 56 consecutive RCC patients with IVC thrombus between January 1994 and December 2016, 41 patients who underwent radical nephrectomy (RN) were categorized as upfront RN (Upfront group) or presurgical axitinib followed by RN (Presurgical group)...
July 27, 2017: International Journal of Clinical Oncology
journal
journal
32641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"